Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 11, Issue 23, 2005, Pages 8413-8417

  Kasamon, Yvette L ^a,d   Flinn, Ian W ^a   Grever, Michael R ^b   Diehl, Louis F ^c   Garrett Mayer, Elizabeth ^a   Goodman, Steven N ^a   Lucas, Margaret S ^b   Byrd, John C ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAPSONE; FLUDARABINE; PLACEBO; PURINE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE DEFICIENCY; INFECTION; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOMA; MALE; MENTAL HEALTH; OPPORTUNISTIC INFECTION; PHASE 1 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SKIN TOXICITY; STATISTICAL MODEL; STREPTOCOCCUS INFECTION; TUMOR IMMUNITY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4 LYMPHOCYTE COUNT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LONGITUDINAL STUDIES; LYMPHOMA, FOLLICULAR; LYMPHOMA, SMALL LYMPHOCYTIC; MALE; MIDDLE AGED; VIDARABINE;

EID: 28544448122     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1612     Document Type: Article

References (30)

1. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13:2431-48.
2. Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993;50:292-6.
3. Bergmann L, Fenchel K, Jahn B, Mitrou PS, Hoelzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993;4:371-5.
4. Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001;19:3611-21.
5. Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995;49:135-42.
6. Byrd JC, McGrail LH, Hospenthal DR, Howard RS, Dow NA, Diehl LF. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Br J Haematol 1999;105:445-7.
7. Priebe T, Platsoucas CD, Seki H, Fox FE, Nelson JA. Purine nucleoside modulation of functions of human lymphocytes. Cell Immunol 1990;129:321-8.
8. Fenchel K, Bergmann L, Wijermans P, et al. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma 1995;18:485-92.
9. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165-71.
10. Hochster HS, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up-a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000;18:987-94.
11. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001;19:1414-20.
12. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000;96:71-5.
13. Cunningham-Rundles C, Murray HW, Smith JP. Treatment of idiopathic CD4 T lymphocytopenia with IL-2. Clin Exp Immunol 1999;116:322-5.
14. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995;332:567-75.
15. Boise LH, Minn AJ, June CH, Lindsten T, Thompson CB. Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. Proc Natl Acad Sci U S A 1995;92:5491-5.
16. Mor F, Cohen IR. IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis. Correlation with induction of Bcl-2. J Immunol 1996;156:515-22.
17. Dmoszynska A, Legiec W, Wach M. Attempted reconstruction of the immune system using low doses of interleukin 2 in chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine: results of a pilot study. Leuk Lymphoma 1999;34: 335-40.
18. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
19. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
21. Pinheiro JC, Bates DM. Mixed-effects models in S and S-plus, 1st ed. New York: Springer-Verlag; 2000.
22. Raferty AE. Bayesian model selection in social research (with discussion). In: Marsden PV, editor. Sociological methodology. Edition. Cambridge (MA): Blackwell Publishers; 1995. p. 111-96.
23. Seki H, Iwai K, Kanegane H, et al. Differential protective action of cytokines on radiation-induced apoptosis of peripheral lymphocyte subpopulations. Cell Immunol 1995;163:30-6.
24. Waselenko JK, Burrows A, Nelson, DA, et al. Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity. Ann Hematol 2003;82:552-7.
25. von Rohr A, Betticher DC, Fey MF, Racine C, Tobler A, Cerny T. Treatment with combined 2-chlorodeoxyadenosine (CDA) and interleukin-2 (IL-2) for low-grade B cell malignancies: a pilot study [abstract]. Proc Am Soc Clin Oncol 1997;16:18a, abstract 63.
26. Fenchel K, Hoffmann J, Borghardt H, et al. Interleukin 2 reduces the CD4+ cell depletion following fludarabine and idarubicin combination therapy [abstract]. Br J Haematol 1998;102:89.
27. Eisenbeis CF, Grainger A, Fischer B, et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a pre-clinical and phase I study. Clin Cancer Res 2004; 10:6101-10.
28. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 2002;117:828-34.
29. Gluck WL, Hurst D. Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004;10:2253-64.
30. Slingluff CL, Jr., Chianese-Bullock K, Yamshchikov G. Interleukin-2 effects deserve further study: a need for better understanding of biology and of optimal dose regimens. J Clin Oncol 2005;23:5267-8.